These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Psoriatic Arthritis.
Method of administration: Subcutaneous, Intravenous
FDA approval date: September 25, 2009
Classification: Interleukin-12 Antagonist
STELARA ® is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy.
Method of administration: Subcutaneous, Intravenous
FDA approval date: April 25, 2009
Classification: Tumor Necrosis Factor Blocker
SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.